Literature DB >> 32980497

Reduction of Lung Metastases in a Mouse Osteosarcoma Model Treated With Carbon Ions and Immune Checkpoint Inhibitors.

Alexander Helm1, Walter Tinganelli1, Palma Simoniello2, Fuki Kurosawa3, Claudia Fournier1, Takashi Shimokawa3, Marco Durante4.   

Abstract

PURPOSE: The combination of radiation therapy and immunotherapy is recognized as a very promising strategy for metastatic cancer treatment. The purpose of this work is to compare the effectiveness of x-ray and high-energy carbon ion therapy in combination with checkpoint inhibitors in a murine model. METHODS AND MATERIALS: We used an osteosarcoma mouse model irradiated with either carbon ions or x-rays in combination with 2 immune checkpoint inhibitors (anti-PD-1 and anti-CTLA-4). LM8 osteosarcoma cells were injected in both hind limbs of female C3H/He mice 7 days before exposure to carbon ions or x-rays. In experimental groups receiving irradiation, only the tumor on the left limb was exposed, whereas the tumor on the right limb served as an abscopal mimic. Checkpoint inhibitors were injected intraperitoneally 1 day before exposure as well as concomitant to and after exposure. Tumor growth was measured regularly up to day 21 after exposure, when mice were sacrificed. Both tumors as well as lungs were extracted.
RESULTS: A reduced growth of the abscopal tumor was most pronounced after the combined protocol of carbon ions and the immune checkpoint inhibitors administered sequentially. Radiation or checkpoint inhibitors alone were not sufficient to reduce the growth of the abscopal tumors. Carbon ions alone reduced the number of lung metastases more efficiently than x-rays, and in combination with immunotherapy both radiation types essentially suppressed the metastasis, with carbon ions being again more efficient. Investigation of the infiltration of immune cells in the abscopal tumors of animals treated with combination revealed an increase in CD8+ cells.
CONCLUSIONS: Combination of checkpoint inhibitors with high-energy carbon ion radiation therapy can be an effective strategy for the treatment of advanced tumors.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32980497     DOI: 10.1016/j.ijrobp.2020.09.041

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  12 in total

1.  Proton beam radiotherapy combined with anti-PD1/PDL1 immune checkpoint inhibitors for advanced hepatocellular carcinoma.

Authors:  Chung-Wei Su; Ming-Mo Hou; Pei-Wei Huang; Yung-Chih Chou; Bing-Shen Huang; Jeng-Hwei Tseng; Chao-Wei Hsu; Tung-Chieh Chang; Shi-Ming Lin; Chen-Chun Lin
Journal:  Am J Cancer Res       Date:  2022-04-15       Impact factor: 5.942

2.  Radioactive Beams for Image-Guided Particle Therapy: The BARB Experiment at GSI.

Authors:  Daria Boscolo; Daria Kostyleva; Mohammad Javad Safari; Vasiliki Anagnostatou; Juha Äystö; Soumya Bagchi; Tim Binder; Georgios Dedes; Peter Dendooven; Timo Dickel; Vasyl Drozd; Bernhard Franczack; Hans Geissel; Chiara Gianoli; Christian Graeff; Tuomas Grahn; Florian Greiner; Emma Haettner; Roghieh Haghani; Muhsin N Harakeh; Felix Horst; Christine Hornung; Jan-Paul Hucka; Nasser Kalantar-Nayestanaki; Erika Kazantseva; Birgit Kindler; Ronja Knöbel; Natalia Kuzminchuk-Feuerstein; Bettina Lommel; Ivan Mukha; Chiara Nociforo; Shunki Ishikawa; Giulio Lovatti; Munetaka Nitta; Ikechi Ozoemelam; Stephane Pietri; Wolfgang R Plaß; Andrej Prochazka; Sivaji Purushothaman; Claire-Anne Reidel; Heidi Roesch; Fabio Schirru; Christoph Schuy; Olga Sokol; Timo Steinsberger; Yoshiki K Tanaka; Isao Tanihata; Peter Thirolf; Walter Tinganelli; Bernd Voss; Uli Weber; Helmut Weick; John S Winfield; Martin Winkler; Jianwei Zhao; Christoph Scheidenberger; Katia Parodi; Marco Durante
Journal:  Front Oncol       Date:  2021-08-19       Impact factor: 5.738

3.  A Consistent Protocol Reveals a Large Heterogeneity in the Biological Effectiveness of Proton and Carbon-Ion Beams for Various Sarcoma and Normal-Tissue-Derived Cell Lines.

Authors:  Masashi Yagi; Yutaka Takahashi; Kazumasa Minami; Taeko Matsuura; Jin-Min Nam; Yasuhito Onodera; Takashi Akagi; Takuya Maeda; Tomoaki Okimoto; Hiroki Shirato; Kazuhiko Ogawa
Journal:  Cancers (Basel)       Date:  2022-04-15       Impact factor: 6.575

4.  Physics and biomedical challenges of cancer therapy with accelerated heavy ions.

Authors:  Marco Durante; Jürgen Debus; Jay S Loeffler
Journal:  Nat Rev Phys       Date:  2021-09-17

Review 5.  Carbon Ion Radiobiology.

Authors:  Walter Tinganelli; Marco Durante
Journal:  Cancers (Basel)       Date:  2020-10-17       Impact factor: 6.575

Review 6.  The Potentiation of Anti-Tumor Immunity by Tumor Abolition with Alpha Particles, Protons, or Carbon Ion Radiation and Its Enforcement by Combination with Immunoadjuvants or Inhibitors of Immune Suppressor Cells and Checkpoint Molecules.

Authors:  Yona Keisari; Itzhak Kelson
Journal:  Cells       Date:  2021-01-25       Impact factor: 6.600

Review 7.  Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier.

Authors:  Somayeh Vafaei; Angelina O Zekiy; Ramadhan Ado Khanamir; Burhan Abdullah Zaman; Arman Ghayourvahdat; Hannaneh Azimizonuzi; Majid Zamani
Journal:  Cancer Cell Int       Date:  2022-01-03       Impact factor: 5.722

Review 8.  Research Progress of Heavy Ion Radiotherapy for Non-Small-Cell Lung Cancer.

Authors:  Siqi Liang; Guangming Zhou; Wentao Hu
Journal:  Int J Mol Sci       Date:  2022-02-19       Impact factor: 5.923

Review 9.  From Photon Beam to Accelerated Particle Beam: Antimetastasis Effect of Combining Radiotherapy With Immunotherapy.

Authors:  Liqiu Ma
Journal:  Front Public Health       Date:  2022-03-29

Review 10.  Current Prospects for Treatment of Solid Tumors via Photodynamic, Photothermal, or Ionizing Radiation Therapies Combined with Immune Checkpoint Inhibition (A Review).

Authors:  Sanjay Anand; Timothy A Chan; Tayyaba Hasan; Edward V Maytin
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.